SARS-CoV-2 Infection During Induction Chemotherapy in a Child With High-risk T-Cell Acute Lymphoblastic Leukemia.
J Pediatr Hematol Oncol
; 43(6): e804-e807, 2021 08 01.
Article
in English
| MEDLINE | ID: covidwho-760055
ABSTRACT
The clinical course of SARS-CoV-2 infection (COVID-19) in children with hematologic malignancies is unclear. We describe the diagnosis, treatment and outcome of a 4-year-old boy with high-risk acute lymphoblastic leukemia and COVID-19. Regardless of immunosuppressive induction chemotherapy his symptoms remained moderate. He received only supportive treatment. Seroconversion occurred in a similar period as in immunocompetent adults. Despite prolonged myelosuppression he did neither acquire secondary infections nor did the treatment delay caused by the infection have a measurable negative impact on the residual disease of acute lymphoblastic leukemia. Intriguingly, residual leukemia even decreased even though he did not receive any antileukemic therapy.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Neoplasm, Residual
/
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
/
Induction Chemotherapy
/
SARS-CoV-2
/
COVID-19
Type of study:
Case report
/
Prognostic study
Topics:
Long Covid
Limits:
Child, preschool
/
Humans
/
Male
Language:
English
Journal:
J Pediatr Hematol Oncol
Journal subject:
Hematology
/
Neoplasms
/
Pediatrics
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS